Get started
meitshel

DARE bullish upcoming catalysts in 2021 and 2022

Long
Dare Bioscience, Inc. (NASDAQ:DARE)  
meitshel Updated   
NASDAQ:DARE   Dare Bioscience, Inc.
Trend Analysis Fundamental Analysis
4
1
trendanalysis fundamental
No Investment advice!

Only for practicing.

Interessting volume spikes in the past.

Upcoming Catalsyst:


NDA Filling
DARE-BV1
Bacterial Vaginosis
1H 2021 Phase 3 trial met primary endpoint - December 7, 2020. NDA planned for 1H 2021.

Phase 1
DARE-HRT1
Hormone replacement therapy
2021 Phase 1 initiation announced July 27, 2020. Data due 2021.

Phase 2b
Sildenafil Cream, 3.6%
Female Sexual Arousal Disorder (FSAD)
2021 Phase 1 initiation announced July 27, 2020. Data due 2021.


Phase 3
Ovaprene
Contraception
2022 Pivotal trial data due in 2022.
Comment:
Trade closed: target reached:
nice spike! Hit my Target
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.